KP Tissue Rating Reiterated by RBC Capital (KPT)
KP Tissue (TSE:KPT)‘s stock had its “outperform” rating reiterated by RBC Capital in a research note issued on Tuesday, Stock Ratings Network reports. They currently have a C$18.00 price objective on the stock, down from their previous price objective of C$19.00. RBC Capital’s price target would indicate a potential upside of 19.28% from the company’s current price.
Shares of KP Tissue (TSE:KPT) traded up 1.39% on Tuesday, hitting $15.30. 5,450 shares of the company’s stock traded hands. KP Tissue has a one year low of $15.06 and a one year high of $18.81. The stock’s 50-day moving average is $15.96 and its 200-day moving average is $16.79.
KP Tissue (TSE:KPT) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.19) earnings per share for the quarter, missing the analysts’ consensus estimate of $0.14 by $0.33.
The company also recently announced a quarterly dividend, which is scheduled for Tuesday, July 15th. Shareholders of record on Monday, June 30th will be paid a dividend of $0.18 per share. This represents a $0.72 annualized dividend and a dividend yield of 4.77%.
Other equities research analysts have also recently issued reports about the stock. Analysts at Scotiabank cut their price target on shares of KP Tissue from C$20.00 to C$19.00 in a research note on Monday. They now have an “outperform” rating on the stock. Separately, analysts at TD Securities cut their price target on shares of KP Tissue from C$19.00 to C$18.00 in a research note on Monday. They now have a “buy” rating on the stock.
KP Tissue Inc is created to acquire, and its business will be limited to holding, a limited partnership interest in Kruger Products L.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.